Search Results
You are looking at 1 - 1 of 1 items for
- Author: L Ksinantova x
- Refine by access: All content x
Search for other papers by F M Brouwers in
Google Scholar
PubMed
Search for other papers by E F Petricoin III in
Google Scholar
PubMed
Search for other papers by L Ksinantova in
Google Scholar
PubMed
Search for other papers by J Breza in
Google Scholar
PubMed
Search for other papers by V Rajapakse in
Google Scholar
PubMed
Search for other papers by S Ross in
Google Scholar
PubMed
Search for other papers by D Johann in
Google Scholar
PubMed
Search for other papers by M Mannelli in
Google Scholar
PubMed
Search for other papers by B L Shulkin in
Google Scholar
PubMed
Search for other papers by R Kvetnansky in
Google Scholar
PubMed
Search for other papers by G Eisenhofer in
Google Scholar
PubMed
Search for other papers by M M Walther in
Google Scholar
PubMed
Search for other papers by B A Hitt in
Google Scholar
PubMed
Search for other papers by T P Conrads in
Google Scholar
PubMed
Search for other papers by T D Veenstra in
Google Scholar
PubMed
Search for other papers by D P Mannion in
Google Scholar
PubMed
Search for other papers by M R Wall in
Google Scholar
PubMed
Search for other papers by G M Wolfe in
Google Scholar
PubMed
Search for other papers by V A Fusaro in
Google Scholar
PubMed
Search for other papers by L A Liotta in
Google Scholar
PubMed
Search for other papers by K Pacak in
Google Scholar
PubMed
Metastatic lesions occur in up to 36% of patients with pheochromocytoma. Currently there is no way to reliably detect or predict which patients are at risk for metastatic pheochromocytoma. Thus, the discovery of biomarkers that could distinguish patients with benign disease from those with metastatic disease would be of great clinical value. Using surface-enhanced laser desorption ionization protein chips combined with high-resolution mass spectrometry, we tested the hypothesis that pheochromocytoma pathologic states can be reflected as biomarker information within the low molecular weight (LMW) region of the serum proteome. LMW protein profiles were generated from the serum of 67 pheochromocytoma patients from four institutions and analyzed by two different bioinformatics approaches employing pattern recognition algorithms to determine if the LMW component of the circulatory proteome contains potentially useful discriminatory information. Both approaches were able to identify combinations of LMW molecules which could distinguish all metastatic from all benign pheochromocytomas in a separate blinded validation set.
In conclusion, for this study set low molecular mass biomarker information correlated with pheochromocytoma pathologic state using blinded validation. If confirmed in larger validation studies, efforts to identify the underlying diagnostic molecules by sequencing would be warranted. In the future, measurement of these biomarkers could be potentially used to improve the ability to identify patients with metastatic disease.